TACE Combined With RFA/MV Treatment in Hepatocellular Carcinoma Beyond Milan Criterial
NCT ID: NCT03636620
Last Updated: 2018-08-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
110 participants
INTERVENTIONAL
2013-06-30
2018-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of Hepatocellular Carcinoma With Radiofrequency Ablation (RFA) Associated With Postoperative TACE
NCT00730860
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
NCT03642561
TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular Carcinoma
NCT00556803
TACE Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular Carcinoma
NCT02630108
Microwave Ablation Combined With TACE in the Treatment of Unresectable Huge Hepatocellular Carcinoma Huge
NCT03277716
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TACE group
Transcatheter arterial chemoembolization
Transcatheter arterial chemoembolization
Transcatheter arterial chemoembolization
TACE+RFA/MV group
Transcatheter arterial chemoembolization and radiofrequency /microwave ablation
Transcatheter arterial chemoembolization
Transcatheter arterial chemoembolization
radiofrequency ablation/microwave ablation
radiofrequency ablation/microwave ablation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transcatheter arterial chemoembolization
Transcatheter arterial chemoembolization
radiofrequency ablation/microwave ablation
radiofrequency ablation/microwave ablation
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* the presence of a single HCC tumor ≤7 cm in diameter, or multi-nodular HCC tumors (n ≤ 5) small than 7 cm in diameter;
* Child-Pugh A or B
* ECOG score 0-1;
* prothrombin time ≤16 s;
* white cell count ≥3,000/mm3, platelet count ≥40 x 109/L;Hb≥8.5 g/d; ALT/AST≤5×ULN;TB≤3mg/dl;alb≥2.8 g/dl ;Scr ≤2mg/dl
Exclusion Criteria
* received anticancer surgery or procedure within one month before assignment;
* concomitant use of any other anticancer therapy(except immunotherapy and herbal medicine ) ;
* existence of portal of hepatic vein invation or extrahepatic metastases;existence of active infection ;
* upper gastrointestinal hemorrhage within one month ; .other serious illness or medical condition.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fudan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zheng-Gang Ren
professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
zheng-gang Ren, doctor
Role: PRINCIPAL_INVESTIGATOR
Fudan University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
liver cancer institute ,Fudan University
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LC-TACE+RFA/MV
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.